Prefilled syringes (PFS) preferred on pharmacy benefit; vials preferred on medical benefit RALEIGH, N.C., April 20, 2026 /PRNewswire/ -- Accord BioPharma, the U.S. specialty division of Intas ...

On December 1, 2024, Biocon announced that the FDA has approved YESINTEK™ (ustekinumab-kfce), a biosimilar to J&J’s STELARA®. YESINTEK is approved for the treatment of Crohn’s disease, Ulcerative ...

Janssen announced new data from the phase 3 UNIFI maintenance study (N=523) which evaluated ustekinumab subcutaneous (SC) maintenance therapy in adults with moderate to severe ulcerative colitis (UC).

Please provide your email address to receive an email when new articles are posted on . Both drugs showed safety and efficacy at 3 and 6 months. Ustekinumab achieved significantly longer treatment ...

In an extension of a phase II clinical drug trial, ustekinumab (Stelara®) was found to be a safe and effective treatment for lupus over two years of use. Researchers assessed multiple measures of ...

Ustekinumab is a monoclonal antibody, prescribed for psoriasis. The risk or severity of adverse effects can be increased when Ustekinumab is combined with Bacillus calmette-guerin substrain connaught ...

The following article is a part of conference coverage from the 2019 Advances in Inflammatory Bowel Diseases (AIBD) Meeting, being held in Orlando, Florida. The team at MPR will be reporting on the ...

Clinical response to ustekinumab for patients with psoriasis was shown to vary by body region, in which lower extremities were identified as the most difficult to treat. Lower response rates to ...

Samsung Bioepis Co., Ltd. today released its Second Quarter 2026 Biosimilar Market Report, marking the thirteenth edition of ...

The US Food and Drug Administration (FDA) has approved ustekinumab-auub (Wezlana) as a biosimilar to ustekinumab (Stelara) for the treatment of multiple inflammatory conditions. This is the first ...

The monoclonal antibody ustekinumab (Stelara, Janssen Biotech Inc) induces response and remission in active moderate-to-severe Crohn's disease that is refractory to tumor necrosis factor (TNF) ...

Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology and immunology therapies, announced IMULDOSA® (ustekinumab-srlf) is now covered by ...